ScoreWhy is Novelix Pharmaceuticals Ltd ?
1
Poor Management Efficiency with a low ROE of 0.76%
- The company has been able to generate a Return on Equity (avg) of 0.76% signifying low profitability per unit of shareholders funds
2
Low ability to service debt as the company has a high Debt to EBITDA ratio of -0.40 times
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -0.40 times
- The company has been able to generate a Return on Equity (avg) of 0.76% signifying low profitability per unit of shareholders funds
3
Healthy long term growth as Net Sales has grown by an annual rate of 157.44%
4
The company has declared Positive results for the last 4 consecutive quarters
- NET SALES(Latest six months) At Rs 73.59 cr has Grown at 181.31%
- PAT(Latest six months) Higher at Rs 1.91 cr
5
With ROE of 10, it has a Fair valuation with a 5.1 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of NA, its profits have risen by 244%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Novelix Pharma. should be less than 10%
- Overall Portfolio exposure to Retailing should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
157.44%
EBIT Growth (5y)
36.51%
EBIT to Interest (avg)
-0.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
1.18
Tax Ratio
25.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-5.80%
ROE (avg)
0.76%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
51
Industry P/E
33
Price to Book Value
5.08
EV to EBIT
38.14
EV to EBITDA
37.04
EV to Capital Employed
5.32
EV to Sales
0.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.97%
ROE (Latest)
9.96%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend20What is working for the Company
NET SALES(Latest six months)
At Rs 73.59 cr has Grown at 181.31%
PAT(Latest six months)
Higher at Rs 1.91 cr
-3What is not working for the Company
NET SALES(Q)
At Rs 25.19 cr has Fallen at -21.3% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is working for Novelix Pharma.
Profit After Tax (PAT) - Latest six months
At Rs 1.91 cr has Grown at 478.79%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Profit After Tax (PAT) - Latest six months
Higher at Rs 1.91 cr
than preceding 12 month period ended Mar 2026 of Rs 0.97 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
Here's what is not working for Novelix Pharma.
Net Sales - Quarterly
At Rs 25.19 cr has Fallen at -21.3% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 31.99 CrMOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
